Protective effects of Sapindus mukorossi Gaertn against fatty liver disease induced by high fat diet in rats

Peng, Qiuxian; Zhang, Qin; Xiao, Wei; Shao, Meng; Fan, Qin; Zhang, Hongwei; Zou, Yukai; Li, Xin; Xu, Wenxue; Mo, Zhixian; Cai, Hongwei

doi:10.1016/j.bbrc.2014.06.035

Cited by 17 publications

(13 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies by Chinese have reported Sapindus mukorossi Gaertn skin is rich in saponins and has properties to regulate fat metabolism and to grant protection to the endothelial cells of blood vessels. However, researchs to provide detailed information about the efficacy of Sapindus mukorossi Gaertn in the prevention and treatment of NAFLD are scarce [ 120 ]. Peng et al [ 120 ] evaluated in a rat model of NAFLD treatment with an alcohol extract of Sapindus mukorossi Gaertn (AESM) in high dosage (0.5 g/kg), moderate dosage (0.1 g/kg) and low dose (0.05 g/kg).…”

Section: Therapeutic Agentsmentioning

confidence: 99%

“…However, researchs to provide detailed information about the efficacy of Sapindus mukorossi Gaertn in the prevention and treatment of NAFLD are scarce [ 120 ]. Peng et al [ 120 ] evaluated in a rat model of NAFLD treatment with an alcohol extract of Sapindus mukorossi Gaertn (AESM) in high dosage (0.5 g/kg), moderate dosage (0.1 g/kg) and low dose (0.05 g/kg). The researchers found that high doses of AESM could relieve AST, ALT, TC, triglycerides, LDL-C, GGT, and also raise HDL-C. Also, the morphology of liver tissue and liver cells began to be normal with this treatment [ 120 ].…”

Section: Therapeutic Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease

Hernández-Rodas

Valenzuela

Videla

2015

IJMS

114

101

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver disease worldwide. NAFLD is linked to circumstances such as type 2 diabetes, insulin resistance, obesity, hyperlipidemia, and hypertension. Since the obesity figures and related comorbidities are increasing, NAFLD has turned into a liver problem that has become progressively more common. Currently, there is no effective drug therapy for NAFLD; therefore, interventions in lifestyles remain the first line of treatment. Bearing in mind that adherence rates to this type of treatment are poor, great efforts are currently focused on finding novel therapeutic agents for the prevention in the development of hepatic steatosis and its progression to nonalcoholic steatohepatitis and cirrhosis. This review presents a compilation of the scientific evidence found in the last years showing the results of interventions in lifestyle, diet, and behavioral therapies and research results in human, animal and cell models. Possible therapeutic agents ranging from supplementation with vitamins, amino acids, prebiotics, probiotics, symbiotics, polyunsaturated fatty acids and polyphenols to interventions with medicinal plants are analyzed.

show abstract

Section: Therapeutic Agentsmentioning

confidence: 99%

Section: Therapeutic Agentsmentioning

confidence: 99%

Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease

Hernández-Rodas

Valenzuela

Videla

2015

IJMS

114

101

View full text Add to dashboard Cite

show abstract

“…C-GT is often associated with the malignant transformation of, cells which is not expressed in mature liver cells. In the course of animal liver cancer, c-GT is regarded as a positive marker of early hepatocellular variation and as the characteristic index of a precancerous liver lesion [36]. Compared with the normal control group, the contents of TP and ALB significantly decreased and that of T-BIL increased (p < .01), which indicated that the synthetic and metabolic functions of the liver seriously declined in the negative control group.…”

Section: Liver Function Indexes In the Serummentioning

confidence: 98%

N-acetylaminogalactosyl-decorated biodegradable PLGA-TPGS copolymer nanoparticles containing emodin for the active targeting therapy of liver cancer

Dong

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Primary liver cancer (PLC) is one of the most common malignant tumours and has the third highest mortality rate worldwide. An active liver-targeting drug delivery system via the asialoglycoprotein receptors expressed in the hepatic parenchyma cells of mammals has become a research focus for the treatment of PLC. N-acetylaminogalactosyl-poly(lactide-co-glycolide)-succinyl-D-α-tocopherol polyethylene glycol 1000 succinate (GalNAc-PLGA-sTPGS) was synthesized to achieve active liver-targeting properties. Emodin (EMO)-loaded GalNAc-PLGA-sTPGS nanoparticles (EGPTN) were prepared with EMO which was selected for its potential antitumour efficacy. The in vitro cellular uptake, mechanism, cytotoxicity, and apoptosis of HepG2 cells were analyzed. The in vivo therapeutic effects of EGPTN were assessed in a PLC mouse model. The results showed that GalNAc-PLGA-sTPGS was successfully synthesized. The cellular uptake assay demonstrated that coumarin 6-loaded GalNAc-PLGA-sTPGS nanoparticles had superior active liver-targeting properties. The results of the cytotoxity and apoptosis studies indicated that EGPTN achieved the highest levels of cytotoxicity and cell apoptotic rate among the nanoparticles examined. Furthermore, EGPTN showed better in vivo therapeutic effects and anticancer efficacy in the PLC mice than did the other groups. Therefore, EGPTN enhanced the anticancer effect of EMO both in vitro and in vivo, making it a potential option for the treatment of PLC.

show abstract

“…The glycosides isolated Downloaded by [New York University] at 03:01 14 July 2015 from S. mukorossi are mainly sesquiterpene oligoglycosides and triterpenoidal saponins of hederagenin, dammarane and tirucullane (Upadhyay & Singh 2012). These glycosides have antimicrobial (Ibrahim et al 2006), cytotoxic (Chen et al 2010), molluscicidal (Huang et al 2003;Upadhyay & Singh 2011), insecticidal (Rahman et al 2007), fungicidal (Supradip et al 2010) and hepatoprotective (Peng et al 2014) properties. In this study, we isolated and characterized two new glycosides and evaluated the in vitro antiproliferative activity of all compounds against A549 cells.…”

Section: Introductionmentioning

confidence: 96%

Two new glycosides isolated fromSapindus mukorossifruits: effects on cell apoptosis and caspase-3 activation in human lung carcinoma cells

Zhang

Yang

Xie

et al. 2015

Natural Product Research

View full text Add to dashboard Cite

Two new glycosides (1, 2) and two saponins (3, 4) were isolated from the fruits of Sapindus mukorossi Gaertn. The two glycosides were designated as sapindoside G (1) and 4'',4'''''-O-diacetylmukurozioside IIa (2). All four compounds exhibited inhibitory effects against A549 human lung adenocarcinoma cells with inhibition rates up to 69.2-83.3% at a concentration of 100 μg/mL. Flow cytometric analysis revealed that compounds 1-4 could suppress A549 cell growth by promoting cell apoptosis, which was related to the activation of caspase-3.

show abstract

Protective effects of Sapindus mukorossi Gaertn against fatty liver disease induced by high fat diet in rats

Cited by 17 publications

References 16 publications

Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease

Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease

N-acetylaminogalactosyl-decorated biodegradable PLGA-TPGS copolymer nanoparticles containing emodin for the active targeting therapy of liver cancer

Two new glycosides isolated fromSapindus mukorossifruits: effects on cell apoptosis and caspase-3 activation in human lung carcinoma cells

Contact Info

Product

Resources

About